QQ客服 官方微博 反馈留言

	EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
	Zhao, Jialiang; Li, Xiaoxin; Tang, Shibo; Xu, Gezhi; Xu, Xun; Zhang, Feng; Zhang, Meixia; Shamsazar, Jila; Pilz, Stefan; Nieweg, Annette
	2014
卷号	28期号:6页码:527-536
ISSN号	1173-8804
DOI	10.1007/s40259-014-0106-1
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6685572
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhao, Jialiang,Li, Xiaoxin,Tang, Shibo,et al. EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration[J],2014,28(6):527-536.
APA	Zhao, Jialiang.,Li, Xiaoxin.,Tang, Shibo.,Xu, Gezhi.,Xu, Xun.,...&Nieweg, Annette.(2014).EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.,28(6),527-536.
MLA	Zhao, Jialiang,et al."EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration".28.6(2014):527-536.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。